Health Catalyst (NASDAQ:HCAT) General Counsel Benjamin Landry Sells 6,175 Shares

Key Points

• Benjamin Landry, the General Counsel of Health Catalyst, sold 6,175 shares at an average price of $3.35, reducing his position by 4.17%.
• Analysts have recently downgraded Health Catalyst, with target prices now ranging between $3.00 and $5.00, leading to a consensus rating of "Hold" with an average target price of $4.73.
• Institutional investors hold a significant stake, owning 85% of Health Catalyst’s stock, demonstrating strong interest from hedge funds and asset management firms.

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) General Counsel Benjamin Landry sold 6,175 shares of the firm's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $3.35, for a total transaction of $20,686.25. Following the completion of the sale, the general counsel owned 141,812 shares of the company's stock, valued at approximately $475,070.20. The trade was a 4.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Health Catalyst Stock Performance

Shares of HCAT stock traded up $0.02 during trading hours on Tuesday, reaching $3.40. 641,764 shares of the company's stock were exchanged, compared to its average volume of 730,463. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.83 and a quick ratio of 1.83. The company's 50 day moving average is $3.58 and its two-hundred day moving average is $3.90. The company has a market cap of $239.26 million, a P/E ratio of -2.25 and a beta of 1.53. Health Catalyst, Inc. has a 1 year low of $2.52 and a 1 year high of $9.24.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HCAT. Piper Sandler downgraded Health Catalyst from an "overweight" rating to a "neutral" rating and reduced their target price for the company from $8.00 to $4.00 in a report on Wednesday, August 27th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $4.00 price objective (down previously from $9.00) on shares of Health Catalyst in a research note on Friday, August 8th. Summit Redstone set a $5.00 price objective on shares of Health Catalyst in a report on Friday, August 29th. Citigroup cut shares of Health Catalyst from a "buy" rating to a "neutral" rating and dropped their target price for the company from $6.50 to $3.50 in a report on Friday, August 8th. Finally, Evercore ISI lifted their price target on shares of Health Catalyst from $3.00 to $4.00 and gave the company an "in-line" rating in a research report on Thursday, August 28th. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $4.73.

Institutional Investors Weigh In On Health Catalyst

Hedge funds and other institutional investors have recently modified their holdings of the company. First Light Asset Management LLC lifted its stake in shares of Health Catalyst by 17.2% during the second quarter. First Light Asset Management LLC now owns 12,230,181 shares of the company's stock valued at $46,108,000 after buying an additional 1,793,374 shares during the period. Nepsis Inc. lifted its stake in shares of Health Catalyst by 2,072.1% during the 1st quarter. Nepsis Inc. now owns 2,090,812 shares of the company's stock worth $9,471,000 after purchasing an additional 1,994,555 shares during the period. Primecap Management Co. CA lifted its stake in shares of Health Catalyst by 3.8% during the 1st quarter. Primecap Management Co. CA now owns 2,005,116 shares of the company's stock worth $9,083,000 after purchasing an additional 72,499 shares during the period. Whetstone Capital Advisors LLC acquired a new stake in shares of Health Catalyst during the first quarter worth $7,724,000. Finally, Geode Capital Management LLC grew its position in shares of Health Catalyst by 11.4% in the second quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company's stock valued at $6,269,000 after purchasing an additional 169,580 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.